Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included a call by President Barack Obama for ensuring there's more opportunities for women in the fields of science, technology, engineering and math, with the man in the White House declaring the US is not going to succeed if half the team members – especially when it's the smarter half – are left on the bench and not allowed to play; charges by the Generic Pharmaceutical Association and its affiliated Biosimilars Council in public comments that AbbVie Inc.'s citizen petition demanding a public hearing must be held before the FDA issues its long-awaited biosimilars guidance on interchangebility was nothing more than a "thinly disguised" ploy to block cheaper biologics that may be substituted for the brand-name products; the release of a new report by the FDA showing the agency permitted more than 700 cheaper versions of brand-name medicines onto the US market in 2015 – more than ever before; and a warning from top US health officials the Zika virus that's been spreading throughout the Americas over the past several months is "scarier" than initially thought and therefore, Congress should no longer delay Obama's $1.9bn funding request to address the situation; plus other Washington news.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts